AnaptysBio's Royalty Stream Prints Cash but the Pipeline Still Burns It

AnaptysBio (NASDAQ: ANAB) is scheduled to report first-quarter 2026 earnings on May 11, 2026, with analysts expecting a loss of $0.31 per share on revenue of approximately $27.5 million. The report comes as the biotech has delivered two consecutive quarters of surprise profitability, raising questions about whether the company can sustain positive earnings momentum or revert to losses as consensus forecasts suggest. With the stock trading near multi-year highs and analyst sentiment strongly bullish, investors will scrutinize whether ANAB's clinical pipeline progress and partnership economics can support the current valuation.

Part 1: Earnings Preview

AnaptysBio is a clinical-stage biotechnology company focused on developing therapeutic antibody candidates for immunology and inflammation, leveraging its proprietary somatic hypermutation platform to generate optimized human antibodies. The company's pipeline addresses dermatological and inflammatory disorders, with multiple programs in clinical development.

For the quarter ending March 2026, analysts expect ANAB to report a loss of $0.31 per share on revenue of approximately $27.5 million. This represents a significant improvement from the $1.28 loss reported in the same quarter last year and follows the company's most recent quarter (December 2025), which delivered earnings of $1.58 per share and revenue of $108.25 million—a substantial beat that exceeded estimates by 77.53%. However, the sharp sequential decline in expected revenue (from $108.25M to $27.5M) reflects the lumpy nature of biotech partnership payments and milestone recognition.

Three key themes define this earnings story:

Clinical Pipeline Advancement: Investors will focus on updates regarding ANAB's lead programs and any progress in moving candidates through clinical trials. Recent analyst commentary suggests optimism around the company's dermatology-focused assets, with multiple firms raising price targets following positive data readouts. The sustainability of the company's development trajectory and any new partnership announcements will be critical.

Revenue Volatility and Partnership Economics: The dramatic quarter-to-quarter swings in revenue—from $108.25M in Q4 2025 to an expected $27.5M in Q1 2026—highlight the episodic nature of biotech revenue recognition tied to milestones and collaboration payments. Analysts will seek clarity on the timing of future payments and whether the company can establish more predictable revenue streams.

Path to Sustained Profitability: After posting positive earnings in Q3 and Q4 2025 (reporting $0.52 and $1.58 per share respectively), the consensus now expects ANAB to return to losses in Q1 2026. The key question is whether recent profitability was driven by one-time partnership payments or reflects improving operational efficiency that could support sustained positive earnings.

Ahead of the release, Wall Street analysts remain overwhelmingly bullish. Stifel Nicolaus raised its price target from $56 to $85 with a "buy" rating following the Q4 beat, citing strong execution and pipeline potential. Wedbush increased its target from $60 to $75, while Barclays maintains a $63 target with an "overweight" rating. However, some caution emerged in April when Barclays reduced its target from $79 to $63, and UBS cut its target from $90 to $60, suggesting concerns about valuation at current levels. The consensus among nine analysts covering the stock points to an average loss of $0.93 per share for Q1, though estimates have been revised upward significantly over the past 30 days—from a loss of $1.11 to the current $0.31 consensus—indicating improving sentiment as the report approaches.

Part 2: Historical Earnings Performance

AnaptysBio has established a strong pattern of exceeding analyst expectations, beating consensus EPS estimates in each of the last four quarters. The magnitude of these beats has been substantial and accelerating: the company delivered a modest 1.54% surprise in Q1 2025, followed by a 10.67% beat in Q2 2025, then dramatically outperformed with a 149.06% surprise in Q3 2025 (reporting $0.52 versus an expected loss of $1.06), and most recently posted a 77.53% beat in Q4 2025 (earning $1.58 against a $0.89 estimate).

The trend reveals a fundamental shift in the company's financial trajectory. The first two quarters of 2025 showed ANAB narrowing losses more than expected, with reported losses of $1.28 and $1.34 compared to estimates of $1.30 and $1.50 respectively. However, the second half of 2025 marked an inflection point, with the company swinging to profitability in both Q3 and Q4—a development that caught analysts off guard given their expectations for continued losses. This pattern of consistent outperformance, particularly the magnitude of recent surprises, suggests either conservative analyst modeling or genuine operational improvements that the Street has been slow to recognize. The upcoming Q1 2026 report will test whether this positive momentum can continue or if the expected return to losses (consensus of -$0.31) proves accurate.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

AnaptysBio typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price behavior around ANAB earnings shows significant volatility, with the stock averaging an absolute move of 7.09% on Day +1 (the first full trading session after results) and an intraday range of 13.17% during that session. The most recent earnings release on March 3, 2026, exemplifies this pattern: the stock declined 3.79% on Day 0 but then surged 14.61% on Day +1 following the strong Q4 beat, with an intraday range exceeding 16%.

The direction of moves has been mixed but generally positive in recent quarters. Following the November 2025 report, ANAB gained 3.63% on Day +1, while the August 2025 release triggered a 9.63% decline despite the earnings beat. Earlier reports in 2024 and early 2025 showed more muted reactions, with Day +1 moves ranging from -10.75% to +11.72%. The data suggests that while ANAB consistently beats estimates, the stock's reaction depends heavily on forward guidance and revenue composition rather than the headline EPS number alone. Investors should prepare for substantial volatility, with historical ranges indicating potential swings of 10-15% in either direction following the May 11 report.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.65% expected move for the May 15 expiration (7 days out), which sits above the historical Day 0 average of 2.66% but slightly below the Day +1 average move of 7.09%. This suggests options traders are anticipating volatility in line with recent historical patterns, though the 13.17% average Day +1 intraday range indicates potential for moves beyond what the current options pricing implies.

Part 3: What Analysts Are Saying

Analyst sentiment on AnaptysBio is overwhelmingly bullish, with the stock carrying a consensus rating that translates to a strong buy recommendation. The current breakdown shows 12 Strong Buy ratings, 0 Moderate Buys, 1 Hold, and no Sell ratings among the 13 analysts covering the stock. The average recommendation score of 4.85 out of 5.0 reflects near-unanimous bullishness, with the consensus price target of $78.75 implying approximately 13.6% upside from the current price of $69.33.

The range of price targets is notably wide, spanning from a low of $50.00 to a high of $140.00, suggesting divergent views on the company's ultimate value despite the overall positive sentiment. The $140 high-end target implies more than 100% upside potential, while even the most conservative $50 target sits only 28% below current levels, indicating limited downside risk in analysts' base-case scenarios.

Sentiment has improved over the past month, with the average recommendation strengthening from 4.71 to 4.85 and one analyst upgrading from Hold to Strong Buy. This positive shift follows the company's strong Q4 2025 earnings beat and reflects growing confidence in ANAB's clinical pipeline and partnership strategy. The timing of these upgrades—coming just ahead of the Q1 2026 report—suggests analysts believe the positive momentum can continue despite consensus expectations for a return to quarterly losses. The concentration of Strong Buy ratings and the recent sentiment improvement indicate Wall Street views current levels as an attractive entry point, even after the stock's substantial rally from its 52-week low of $17.11.

Part 4: Technical Picture

AnaptysBio enters its May 11 earnings report with exceptionally strong technical momentum. The Barchart Technical Opinion currently registers a 100% Buy signal, maintaining this maximum bullish reading consistently over the past week and month, indicating sustained positive momentum heading into the release.

Timeframe Analysis:

• Short-term (100% Buy): Maximum buy signal reflects powerful near-term momentum as the stock trades at multi-year highs
• Medium-term (100% Buy): Continued strength in the intermediate timeframe confirms the uptrend is well-established across multiple time horizons
• Long-term (100% Buy): Maximum long-term buy signal indicates the broader trend has fully reversed from previous weakness

Trend Characteristics: The stock ranks in the Top 1% with the Strongest directional momentum, placing ANAB among the most technically robust names in the market as it approaches earnings.

The stock is trading above all major moving averages, confirming a powerful uptrend across all timeframes. ANAB currently sits at $69.33, above its 5-day moving average of $68.54, 10-day average of $67.02, 20-day average of $58.21, 50-day average of $47.85, 100-day average of $40.35, and 200-day average of $30.09. This alignment—with each shorter-term average above each longer-term average—represents a classic bullish configuration where momentum is building at an accelerating pace.

The technical setup heading into earnings is decidedly supportive, with the stock in a confirmed uptrend and trading more than 130% above its 200-day moving average. However, this extreme strength also introduces risk: the stock has rallied sharply into the report, potentially leaving it vulnerable to profit-taking if results or guidance disappoint. The 20-day moving average at $58.21 represents the first significant support level, approximately 16% below current prices, while the 50-day average at $47.85 marks a deeper support zone. Given the stock's position at the upper end of its recent range and the historical tendency for 10-15% post-earnings moves, traders should be prepared for heightened volatility regardless of whether the company beats or misses estimates.